Deals channel feed

#ES­MO22: Af­ter day filled with in­vestor, GSK ap­petite, Spring­Works brings out the da­ta for can­cer drug near­ing FDA

3 years ago
Financing
R&D

In­vestor suit fu­eled by news ar­ti­cles over failed can­cer drug ends in $24M set­tle­ment

3 years ago
Law

Af­ter block­ing Grail ac­qui­si­tion, EU leaves Il­lu­mi­na with few good op­tions

3 years ago
Diagnostics

Fol­low­ing luke­warm launch and lay­offs, Zealand Phar­ma is li­cens­ing out its di­a­betes drug to No­vo Nordisk

3 years ago

Good Ther­a­peu­tics sells PD-1 IL-2 pro­gram to Roche for $250M and will march on with a sim­i­lar name, but in Latin

3 years ago
Pharma

A Rich Hey­man biotech backed by a top Salk sci­en­tist is auc­tioned off for its dwin­dling cash re­serves

3 years ago

Up­dat­ed: EU swats down Il­lu­mi­na's $8B Grail ac­qui­si­tion days af­ter FTC lost an­titrust case

3 years ago
Pharma

Seek­ing first-in-class glo­ry, Roche en­lists biotech part­ner that prides it­self on crack­ing 'un­drug­gable' tar­gets

3 years ago

Il­lu­mi­na pre­vails over FTC's chal­lenge of $8B Grail buy­out

3 years ago
Pharma
Law

Thrills, chills, a fi­nal of­fer from Bob Brad­way and a hard­ball threat from 'Par­ty E': the in­sid­er look at the $4B Chemo­Cen­tryx deal

3 years ago

As No­vo Nordisk be­gins PhII sick­le cell tri­al, it snags a lat­er-stage blood dis­or­der drug in $1.1B For­ma buy

3 years ago
Pharma

Af­ter ditch­ing elec­tric ve­hi­cle parts mak­er, a SPAC choos­es a Brown spin­out that had test­ed the IPO wa­ters

3 years ago

Mi­cro­cap car­dio play­er touts a 'siz­able' tech deal with Bay­er's Blue­Rock in wake of 'go­ing con­cern' alert

3 years ago

Aus­tralian man­u­fac­tur­er ac­quired by cap­i­tal in­vest­ment firm with ex­pe­ri­ence in CD­MO space

3 years ago
Manufacturing

With cash in the bank and an eye on Eu­rope, Neu­ro­crine buys out a Lon­don-based out­fit

3 years ago

Pfiz­er buys in­to de­cen­tral­ized co­op­er­a­tive to ac­cel­er­ate R&D in hu­man longevi­ty

3 years ago

Af­ter clin­i­cal hold quashed its hopes, Yu­man­i­ty field­ed 10 bid­ders be­fore land­ing on two-way deal with J&J, Kine­ta

3 years ago

Take­da breaks off five-year pact with mi­cro­bio­me part­ner, hand­ing back two pre­clin­i­cal drugs

3 years ago

No deal for Mer­ck and Seagen yet as talks stall over buy­out price — re­port

3 years ago

Af­ter wrestling with the San­doz prob­lem for sev­er­al years, Vas Narasimhan set­tles on a spin­out

3 years ago

Al­con, No­var­tis' for­mer eye dis­ease unit, con­tin­ues deal­mak­ing spree with $770M Aerie ac­qui­si­tion

3 years ago
R&D

Four of­fers and a call from Bourla: How Pfiz­er nar­row­ly beat out ri­val bid­der to swal­low GBT and its sick­le cell drugs for $5.4B

3 years ago

Roche, Genen­tech plunk down $60M up­front to part­ner with Chi­nese phar­ma on PRO­TAC-based prostate can­cer drug

3 years ago
China

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

3 years ago
AI
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times